Ownership Summary
InMed Pharmaceuticals Inc. (NASDAQ:INM) has 7 institutional investors that have filed 13F reports for the period ending December 2025.
- Their combined ownership stood at 5.7% of outstanding shares in December 2025, down from 7.7% in September 2025.
- They increased total shares held in InMed Pharmaceuticals by 3.06% from last quarter, and the number of investors in INM increased 16.67% annually.
- During the quarter, 3 of these 7 funds increased positions in INM, 1 reduced exposure, and 3 held steady.
- In total, institutional investors held 227.05K shares in InMed Pharmaceuticals as of December 2025, up by 6.74K shares quarter on quarter, and up 178.15K shares year over year.
- SABBY MANAGEMENT, LLC holds the largest position in INM at 201.63K shares as of December 31, 2025, or 5.1% of shares outstanding.
- Top purchasers of INM stock for the quarter ending December 2025 included SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377).
- Top sellers of INM stock for the quarter ending December 2025 included SABBY MANAGEMENT, LLC (18.37K).
- According to Business Quant data, leading holders of INM for December 2025 are SABBY MANAGEMENT, LLC (201.63K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (12.75K), JANE STREET GROUP, LLC (11.98K), UBS Group AG (377), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).